Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists
| Autor: | Spinogatti F, Mignone Ml, De Filippis S, Farinella F, Russo F, Di Lella M, Toscano M, Cenci M, David Fraguas, Giovanni Amodeo, Pillai G, Pataracchia G, Sanchez-Gistau, Andrea Fagiolini, Luis Gutiérrez-Rojas, Ferraiuolo F, Villari, Alfonsi E, Loparco N |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
antipsychotics
Aripiprazole depot injectable LAI long acting maintena switch switching Pharmacology (medical) medicine.medical_specialty Consensus Side effect medicine.drug_class medicine.medical_treatment Atypical antipsychotic 03 medical and health sciences 0302 clinical medicine otorhinolaryngologic diseases medicine Humans Antipsychotic Psychiatry business.industry General Medicine medicine.disease 030227 psychiatry Long acting Tolerability Italy Schizophrenia Spain Delayed-Action Preparations Antipsychotic Medications business 030217 neurology & neurosurgery medicine.drug Antipsychotic Agents |
| Zdroj: | Europe PubMed Central |
| ISSN: | 1744-764X |
| Popis: | Aripiprazole long acting once-monthly (AOM) is a long acting atypical antipsychotic with proven efficacy in schizophrenia and with a pharmacological and a side effect profile that is different from other antipsychotics. These and other characteristics make AOM a possible alternative in patients requiring a change in long acting antipsychotic treatment due to issues such as lack of efficacy or persistent side effects. Both clinical and pharmacological factors should be considered when switching antipsychotics, and specific guidelines for long acting antipsychotic switching that address all these factors are needed.A panel of Italian and Spanish experts in psychiatry met to discuss the strategies for the switch to AOM in patients with schizophrenia. Real life clinical experiences were shared and the clinical strategies to improve the likelihood of success were discussed.Due to its specific pharmacological and tolerability profile, AOM represents a suitable alternative for patients with schizophrenia requiring a switch to a new LAI treatment because of lack of efficacy or persistent side effects from another LAI. Possible strategies for the switch to AOM are presented in this expert consensus paper in an attempt to provide guidance throughout the entire switching process. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|